{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:06:13Z","timestamp":1789596373054,"version":"build-2803163510"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>According to current research, the objective response rate and overall survival of pembrolizumab in the treatment of several types of solid tumors have been significantly improved. Some high-quality clinical trials have studied the effect of applying pembrolizumab in treating cervical cancer. Multiple clinical trials have been conducted, and some of them have shown good results as expected. Therefore, we performed this meta-analysis on existing studies to reveal the efficacy and safety of pembrolizumab in treating cervical cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>PubMed, Embase, Cochrane Library and Web of Science were searched for literatures published until October 31, 2021. Outcomes included complete response (CR), partial response (PR), stable disease (SD), disease progression (PD), objective response rate (ORR), disease control rate (DCR), overall survival (OS), progression-free survival (PFS), the best time to response (TTR), death rate, adverse events (AE).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 7 studies with 727 patients were included. The results were as follows: CR (0.027, 95%CI: 0.008-0.053), PR (0.104, 95% CI: 0.074-0.145), SD (0.190, 95% CI: 0.149-0.240), PD (0.541, 95% CI: 0.421-0.661). ORR was 0.155 (95% CI: 0.098-0.236) and DCR was 0.331 (95% CI: 0.277-0.385). OS was 10.23 months (95% CI: 8.96-11.50) and PFS was 4.27 months (95% CI: 1.57-6.96). TTR was 2.10 months (95%CI: 1.69-2.51). The 1-year death rate was 0.388 (95% CI: 0.230-0.574). Main adverse events included abnormal liver function, hypothyroidism, neutropenia, anemia, decreased appetite, fatigue, fever, etc. The total incidence of the adverse events of grade 3 and above was 0.212 (95% CI: 0.065-0.509).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Pembrolizumab provides significant benefits in response rate and survival for cervical cancer patients. The results from recent high-quality clinical trials are expected to validate these findings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:uri>, identifier CRD42021291723.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.910486","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T05:47:13Z","timestamp":1660110433000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy and safety of pembrolizumab on cervical cancer: A systematic review and single-arm meta-analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Lin","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianglin","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21628","article-title":"Cervical cancer screening for individuals at average risk: 2020 guideline update from the American cancer society","volume":"70","author":"Fontham","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1177\/1758834017708742","article-title":"Pembrolizumab in cervical cancer: latest evidence and clinical usefulness","volume":"9","author":"Borcoman","year":"2017","journal-title":"Ther Adv Med Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2015.10.147","article-title":"Cervical cancer screening: evidence behind the guidelines","volume":"214","author":"Lees","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JGO.2016.007534","article-title":"Improving global outcomes in cervical cancer: the time has come for international federation of gynecology and obstetrics staging to formally incorporate advanced imaging","volume":"4","author":"Jolly","year":"2018","journal-title":"J Glob Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2016.27.e51","article-title":"Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research","volume":"27","author":"Lee","year":"2016","journal-title":"J Gynecol Oncol"},{"key":"B7","doi-asserted-by":"crossref","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume-title":"A Cancer Journal for Clinicians","author":"Siegel","year":"2022"},{"key":"B8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1148\/radiol.2019190088","article-title":"2018 FIGO staging system for uterine cervical cancer: enter cross-sectional imaging","volume":"292","author":"Lee","year":"2019","journal-title":"Radiology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.9985","article-title":"Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial","volume":"36","author":"Gupta","year":"2018","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3892\/ol_00000001","article-title":"Treatment options in recurrent cervical cancer","volume":"1","author":"Gadducci","year":"2010","journal-title":"Oncol Lett"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0001","article-title":"NCCN clinical practice guidelines in oncology: cervical cancer","volume":"1","author":"Abu-Rustum","year":"2019","journal-title":"Version"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2021.1850279","article-title":"Pembrolizumab for advanced cervical cancer: safety and efficacy","volume":"21","author":"De Felice","year":"2021","journal-title":"Expert Rev Anticancer Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.27172","article-title":"PD-1\/PD-L1 immune checkpoint: potential target for cancer therapy","volume":"234","author":"Dermani","year":"2019","journal-title":"J Cell Physiol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00914","article-title":"High-risk HPV oncoproteins and PD-1\/PD-L1 interplay in human cervical cancer: recent evidence and future directions","volume":"914","author":"Allouch","year":"2020","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.3390\/ijms22041807","article-title":"Targeting the PD-1 axis with pembrolizumab for recurrent or metastatic cancer of the uterine cervix: A brief update","volume":"22","author":"Verhoeven","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.03.002","article-title":"Patient characteristics, treatment patterns, and clinical outcomes among patients with previously treated recurrent or metastatic cervical cancer: a community oncology-based analysis","volume":"161","author":"Alholm","year":"2021","journal-title":"Gynecol Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"100831","DOI":"10.1016\/j.gore.2021.100831","article-title":"Pattern of disease and response to pembrolizumab in recurrent cervical cancer","volume":"37","author":"Miller","year":"2021","journal-title":"Gynecol Oncol Rep"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.3390\/cancers12113188","article-title":"Real-world experience of pembrolizumab monotherapy in patients with recurrent or persistent cervical cancer: A korean multi-center retrospective study (KGOG1041)","volume":"12","author":"Choi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30486-1","article-title":"Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial","volume":"21","author":"Youn","year":"2020","journal-title":"Lancet Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.5471","article-title":"Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1\u2013positive cervical cancer: results from the phase ib KEYNOTE-028 trial","volume":"35","author":"Frenel","year":"2017","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (MINORS): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"key":"B29","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(18)32470-X","article-title":"Cervical cancer","volume-title":"Lancet","author":"Cohen","year":"2019"},{"key":"B30","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(03)13778-6","article-title":"Cervical cancer","volume-title":"Lancet","author":"Waggoner","year":"2003"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2017.28.e34","article-title":"Randomized study between radical surgery and radiotherapy for the treatment of stage IB\u2013IIA cervical cancer: 20-year update","volume":"28","author":"Landoni","year":"2017","journal-title":"J Gynecol Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/S0020-7292(06)60030-1","article-title":"Carcinoma of the cervix uteri","volume":"95","author":"Quinn","year":"2006","journal-title":"Int J Gynaecol Obstet"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx220","article-title":"Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Marth","year":"2017","journal-title":"Ann Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2016.11.006","article-title":"Management of patients with recurrent\/advanced cervical cancer beyond first line platinum regimens: Where do we stand? a literature review","volume":"108","author":"Boussios","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2165\/11534370-000000000-00000","article-title":"Pharmacotherapy options for locally advanced and advanced cervical cancer","volume":"70","author":"Due\u00f1as-Gonz\u00e1lez","year":"2010","journal-title":"Drugs"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2019-000880","article-title":"A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10\/GEICO 68-C\/JGOG1084\/GOG-3030)","volume":"30","author":"Grau","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2016.10.002","article-title":"The impact of systemic therapy beyond first-line treatment for advanced cervical cancer","volume":"29","author":"McLachlan","year":"2017","journal-title":"Clin Oncol (Royal Coll Radiologists (Great Britain))"},{"key":"B39","doi-asserted-by":"publisher","first-page":"768","DOI":"10.4143\/crt.2017.141","article-title":"Survival nomograms after curative neoadjuvant chemotherapy and radical surgery for stage IB2-IIIB cervical cancer","volume":"50","author":"Marchetti","year":"2018","journal-title":"Cancer Res Treat"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2019.09.030","article-title":"Mechanisms controlling PD-L1 expression in cancer","volume":"76","author":"Cha","year":"2019","journal-title":"Mol Cell"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00065","article-title":"PD-1\/PD-L1 inhibitors in cervical cancer","volume":"65","author":"Liu","year":"2019","journal-title":"Front Pharmacol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1646721","article-title":"Pembrolizumab for the treatment of cervical cancer","volume":"19","author":"Marret","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.172","article-title":"Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio neo-adjuvante portio) Italian collaborative study","volume":"23","author":"Buda","year":"2005","journal-title":"J Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1985.3.8.1079","article-title":"Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a gynecologic oncology group study","volume":"3","author":"Bonomi","year":"1985","journal-title":"J Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/1097-0142(19810815)48:4<899::AID-CNCR2820480406>3.0.CO;2-6","article-title":"Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the gynecologic oncology group","volume":"48","author":"Thigpen","year":"1981","journal-title":"Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19890401)63:7<1283::AID-CNCR2820630709>3.0.CO;2-U","article-title":"Factors affecting the response of recurrent squamous cell carcinoma of the cervix to cisplatin","volume":"63","author":"Potter","year":"1989","journal-title":"Cancer"},{"key":"B48","doi-asserted-by":"publisher","first-page":"4649","DOI":"10.1200\/JCO.2009.21.8909","article-title":"Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a gynecologic oncology group study","volume":"27","author":"Monk","year":"2009","journal-title":"J Clin Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: A review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"B50","doi-asserted-by":"publisher","first-page":"241","DOI":"10.21147\/j.issn.1000-9604.2016.02.14","article-title":"Chemotherapy and molecular targeting therapy for recurrent cervical cancer","volume":"28","author":"Tsuda","year":"2016","journal-title":"Chin J Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1200\/JCO.2008.18.9043","article-title":"Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study","volume":"27","author":"Monk","year":"2009","journal-title":"J Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70004-5","article-title":"Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG oncology\u2013gynecologic oncology group protocol 240)","volume":"16","author":"Penson","year":"2015","journal-title":"Lancet Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic oncology group 240)","volume":"390","author":"Tewari","year":"2017","journal-title":"Lancet"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6874-6-3","article-title":"Routine management of locally advanced cervical cancer with concurrent radiation and cisplatin","volume":"6","author":"Cetina","year":"2006","journal-title":"Five-year Results"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.2147\/DDDT.S106412","article-title":"Molecular mechanisms of cisplatin resistance in cervical cancer","volume":"10","author":"Zhu","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"B56","doi-asserted-by":"publisher","first-page":"Cd013348","DOI":"10.1002\/14651858.CD013348.pub2","article-title":"Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer","volume":"3","author":"Chuai","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"B57","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/proteomes10020016","article-title":"Applications of proteomics in ovarian cancer: Dawn of a new era","volume":"10","author":"Ghose","year":"2022","journal-title":"Proteomes"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1506824","DOI":"10.1155\/2017\/1506824","article-title":"Dynamics of neutrophils-to-Lymphocyte ratio predict outcomes of PD-1\/PD-L1 blockade","volume":"2017","author":"Moschetta","year":"2017","journal-title":"BioMed Res Int"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.910486\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T05:47:16Z","timestamp":1660110436000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.910486\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,10]]},"references-count":58,"alternative-id":["10.3389\/fonc.2022.910486"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.910486","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,10]]},"article-number":"910486"}}